Aridis Pharmaceuticals Inc
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin… Read more
Aridis Pharmaceuticals Inc (ARDS) - Total Assets
Latest total assets as of September 2023: $6.53 Million USD
Based on the latest financial reports, Aridis Pharmaceuticals Inc (ARDS) holds total assets worth $6.53 Million USD as of September 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Aridis Pharmaceuticals Inc - Total Assets Trend (2015–2022)
This chart illustrates how Aridis Pharmaceuticals Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Aridis Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2022)
Aridis Pharmaceuticals Inc's total assets of $6.53 Million consist of 79.1% current assets and 20.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 33.2% |
| Accounts Receivable | $1.24 Million | 8.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $17.00K | 0.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2022)
This chart illustrates how Aridis Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aridis Pharmaceuticals Inc's current assets represent 79.1% of total assets in 2022, a decrease from 91.8% in 2015.
- Cash Position: Cash and equivalents constituted 33.2% of total assets in 2022, down from 74.5% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 8.4% of total assets.
Aridis Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Aridis Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Aridis Pharmaceuticals Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Aridis Pharmaceuticals Inc generates 1.31x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Aridis Pharmaceuticals Inc is currently not profitable relative to its asset base.
Aridis Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.24 | 0.20 | 4.58 |
| Quick Ratio | 0.26 | 0.20 | 5.35 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-13.37 Million | $ -33.64 Million | $ 18.94 Million |
Aridis Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Aridis Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.40 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -45.2% |
| Total Assets | $14.70 Million |
| Market Capitalization | $3.84K USD |
Valuation Analysis
Below Book Valuation: The market values Aridis Pharmaceuticals Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Aridis Pharmaceuticals Inc's assets decreased by 45.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Aridis Pharmaceuticals Inc (2015–2022)
The table below shows the annual total assets of Aridis Pharmaceuticals Inc from 2015 to 2022.
| Year | Total Assets | Change |
|---|---|---|
| 2022-12-31 | $14.70 Million | -45.16% |
| 2021-12-31 | $26.80 Million | +77.26% |
| 2020-12-31 | $15.12 Million | -45.95% |
| 2019-12-31 | $27.97 Million | -11.53% |
| 2018-12-31 | $31.61 Million | +19.39% |
| 2017-12-31 | $26.48 Million | +17.49% |
| 2016-12-31 | $22.54 Million | +480.25% |
| 2015-12-31 | $3.88 Million | -- |